Second Price Cut for PCSK9 Inhibitor Alirocumab (Praluent)

Share this post

The move brings the price down about 60% from the original cost of the cholesterol-lowering drug and brings alirocumab in line with the cost of its competitor PCSK9 inhibitor, evolocumab.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply